Community Practice Connections™: Show Me the Data®: Evidence-Based Strategies to Leverage Immunogenicity in Hepatocellular Carcinoma

Release Date: August 30, 2021
Expiration Date: August 30, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in hepatocellular carcinoma (HCC) to assess the clinical impact of recent and emerging trial data for novel therapies in HCC treatment. Participants will gain insights on how experts in the field of HCC leverage key data sets to support decision-making regarding when to initiate systemic therapy, how to appropriately sequence or combine therapies, how to monitor the patient, and best practices for adverse event management. Future directions in the field are also addressed, including how the results of recent clinical trials may shape the care of patients with HCC.

This educational activity is an archive of the live virtual symposium held on June 9, 2021.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of HCC. Hepatologists, gastroenterologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with HCC will also be invited to participate.
 

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify clinically relevant aspects of HCC biology and biomarkers in the context of treatment planning and therapeutic development
• Evaluate safety and efficacy data from recent clinical trials that inform treatment decision-making across lines of care in HCC
• Assess available data that informs treatment decision-making across multiple lines of care with consideration for prior therapies and toxicities
• Apply relevant data and patient/disease factors to develop personalized therapeutic sequencing strategies for HCC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Tanios Bekaii-Saab, MD, FACP
Professor of Medicine
Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Consultant, Division of Hematology/Oncology
Mayo Clinic Cancer Center
Consortium Chair
Academic and Community Cancer Research United
Phoenix, AZ

Disclosures: Grant Research Support: To institution: AbGenomics Corporation, Agios Pharmaceuticals, Amgen, Array Biopharma, Arys, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis Oncology, Incyte, Ipsen, Eli Lilly and Company, Merck, Genentech, Novartis, Merus, Mirati Therapeutics, Pfizer, Seattle Genetics; Consultant: To institution: Array Biopharma, Bayer, Genentech, Incyte, Ipsen, Merck, Pfizer, Seattle Genetics; To self: AbbVie, AstraZeneca, BeiGene, Boehringer Ingelheim, Celularity, Daiichi Sankyo, Eisai, Exact Sciences, Foundation Medicine, Janssen Pharmaceuticals, Natera, Sobi, Treos Bio, Xilis; IDMC-DSMB, 1Globe Health Institute, AstraZeneca, Exelixis, Lilly, PanCAN; Other: Scientific Advisory Board: Immuneering, Imugene, Sun BioPharma; Inventions/Patents: WO/2018/183488 WO/2019/055687
 

Richard S. Finn, MD

Professor of Medicine, Department of Medicine, Division of Hematology/Oncology

Geffen School of Medicine

Director, Signal Transduction and Therapeutics Area, Jonsson Comprehensive Cancer Center

University of California

Los Angeles, CA

 

Disclosures: Consultant: AstraZeneca, Bayer, Bristol Myers Squibb, CStone Pharmaceuticals, Eisai, Exelixis, Merck, Pfizer, Roche/Genentech
 

Yujin Hoshida MD, PhD
Director, Liver Tumor Translational Research
Simmons Comprehensive Cancer Center
Associate Professor of Internal Medicine
Division of Digestive and Liver Diseases
University of Texas Southwestern Medical Center
Dallas TX
 

Disclosures: Grant Research Support: Morphic Therapeutic; Shareholder: Alentis Therapeutics; Consultant: Helio Health;
 

R. Kate (Katie) Kelley, MD

Professor of Clinical Medicine

Department of Medicine (Hematology/Oncology)

UCSF Helen Diller Family Comprehensive Cancer Center

University of California San Francisco

San Francisco, CA

 

Disclosures: Grant Research Support: Adaptimmune Therapeutics plc, Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly and Company, EMD Serono, Exelixis, Genentech, Merck, Novartis, Partner Therapeutics, QED Therapeutics, Relay Therapeutics, Taiho Pharmaceutical; Consultant/Advisory role: Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Exact Sciences, Genentech, Gilead Sciences; Other: Travel support for satellite symposium from Ipsen

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.